drugset / Trial / NCT02977065
To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors
RandomizedFactorialQuadruple-blindTreatment
Summary
A multicenter, double-blind, parallel-group, active-controlled, dose-ranging study to assess the safety and efficacy of the novel cholesteryl ester transfer protein (CETP) inhibitor CKD-519 in combination with atorvastatin or rosuvastatin in subjects with dyslipidemia.
Timeline
- Start
- 2017-03-23
- Primary completion
- 2017-12-30
- Completion
- 2018-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atorvastatin | Small molecule | 20 mg | Oral |
| Subject | ROCACETRAPIB | Small molecule | 50 mg | Oral |
| Subject | ROCACETRAPIB | Small molecule | 100 mg | Oral |
| Subject | ROCACETRAPIB | Small molecule | 200 mg | Oral |
| Comparator | Rosuvastatin | Small molecule | 10 mg | Oral |